ES2184800T3 - Uso de agentes anti-vegf en el tratamiento de la endometriosis. - Google Patents

Uso de agentes anti-vegf en el tratamiento de la endometriosis.

Info

Publication number
ES2184800T3
ES2184800T3 ES95919578T ES95919578T ES2184800T3 ES 2184800 T3 ES2184800 T3 ES 2184800T3 ES 95919578 T ES95919578 T ES 95919578T ES 95919578 T ES95919578 T ES 95919578T ES 2184800 T3 ES2184800 T3 ES 2184800T3
Authority
ES
Spain
Prior art keywords
endometriosis
treatment
pct
date
vegf agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95919578T
Other languages
English (en)
Inventor
David Stephen Charnock-Jones
John Mclaren
Andrew Prentice
Stephen Kevin Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metris Therapeutics Ltd
Original Assignee
Metris Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metris Therapeutics Ltd filed Critical Metris Therapeutics Ltd
Application granted granted Critical
Publication of ES2184800T3 publication Critical patent/ES2184800T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE MUESTRA : UNA COMPOSICION PARA USAR EN EL TRATAMIENTO DE LA ENDOMETRIOSIS, QUE INCLUYE UN AGENTE CAPAZ DE INTERFERIR LA PRODUCCION Y/O ACTIVIDAD DE VEGF, Y UNA SUSTANCIA DE TRANSPORTE ACEPTABLE FISIOLOGICAMENTE; UNA COMPOSICION PARA EL TRATAMIENTO DE LA ENDOMETRIOSIS QUE INCLUYE UN AGENTE PARA INHIBIR LA ACTIVACION Y/O RECLUTAMIENTO DE MACROFAGOS PERITONEALES, Y UN TRANSPORTE ACEPTABLE FISIOLOGICAMENTE, Y METODOS PARA ELABORAR LAS COMPOSICIONES Y SU USO EN EL TRATAMIENTO DE LA ENDOMETRIOSIS.
ES95919578T 1994-05-26 1995-05-26 Uso de agentes anti-vegf en el tratamiento de la endometriosis. Expired - Lifetime ES2184800T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9410533A GB9410533D0 (en) 1994-05-26 1994-05-26 In situ hybridisation and immuno-Chemical localisation of a growth factor

Publications (1)

Publication Number Publication Date
ES2184800T3 true ES2184800T3 (es) 2003-04-16

Family

ID=10755736

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95919578T Expired - Lifetime ES2184800T3 (es) 1994-05-26 1995-05-26 Uso de agentes anti-vegf en el tratamiento de la endometriosis.

Country Status (11)

Country Link
US (1) US6121230A (es)
EP (1) EP0771192B1 (es)
JP (1) JPH10505321A (es)
AT (1) ATE222488T1 (es)
AU (1) AU692874B2 (es)
CA (1) CA2191070A1 (es)
DE (1) DE69527847T2 (es)
ES (1) ES2184800T3 (es)
GB (1) GB9410533D0 (es)
NZ (1) NZ285833A (es)
WO (1) WO1995032708A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3968597A (en) 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors
WO1998039035A1 (en) 1997-03-07 1998-09-11 The Wistar Institute Of Anatomy & Biology Method and compositions for healing tissue defects and inducing hypervascularity in mammalian tissue
US6753138B1 (en) 1998-06-04 2004-06-22 Reprogen, Inc. Use of prothymosin in the diagnosis and treatment of endometriosis
CA2299436A1 (en) * 1998-06-04 1999-12-09 Reprogen, Inc. Use of prothymosin in the diagnosis and treatment of endometriosis
IL145941A (en) 1999-04-28 2007-08-19 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting vegf
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US6780594B2 (en) * 2000-09-25 2004-08-24 Schering Aktiengesellschaft Method for in vitro diagnosis of endometriosis
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
AU2002319402B2 (en) * 2001-06-28 2008-09-11 Domantis Limited Dual-specific ligand and its use
EP1414964B1 (en) * 2001-08-01 2010-03-24 University Of Bristol Vegf isoform
WO2003018752A2 (en) 2001-08-23 2003-03-06 The Wistar Institute Of Anatomy And Biology An organotypic intestinal culture and methods of use thereof
DE10229379A1 (de) * 2002-06-26 2004-01-29 Schering Ag EG-VEGF Rezeptor Antagonisten
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
EP1600459A3 (en) * 2002-06-28 2005-12-07 Domantis Limited Ligand
JP2006523090A (ja) * 2002-12-27 2006-10-12 ドマンティス リミテッド リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
ATE354592T1 (de) * 2003-03-28 2007-03-15 Regeneron Pharma Vegf-antagonisten zur behandlung von diabetes
WO2004103159A2 (en) * 2003-05-14 2004-12-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for modulating endometrium
GB0320238D0 (en) * 2003-08-29 2003-10-01 Medical Res Council Treatment of disease
US20050214280A1 (en) * 2004-03-02 2005-09-29 Ludwig Institute For Cancer Research Method for inhibiting tumor formation and growth
US8257742B2 (en) * 2005-02-17 2012-09-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Bisphosphonates for treating endometriosis
CN101454344A (zh) * 2005-12-01 2009-06-10 杜门蒂斯有限公司 与白细胞介素-1受体1型结合的非竞争性域抗体形式
ATE476986T1 (de) * 2006-01-18 2010-08-15 Gen Hospital Corp Verfahren zur steigerung der lymphatischen funktion
NZ580530A (en) 2007-06-06 2012-04-27 Domantis Ltd Anti vegf polypeptides, antibody variable domains and antagonists
WO2011073521A1 (en) 2009-12-15 2011-06-23 Petri Salven Methods for enriching adult-derived endothelial progenitor cells and uses thereof
SG187592A1 (en) 2010-07-23 2013-03-28 Univ Boston Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US20130022551A1 (en) 2011-07-22 2013-01-24 Trustees Of Boston University DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
WO2016008975A1 (en) 2014-07-18 2016-01-21 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
US10877045B2 (en) * 2015-07-21 2020-12-29 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3733478A1 (de) * 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
DK1975181T3 (da) * 1992-10-28 2011-06-06 Genentech Inc Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister
WO1994021679A1 (en) * 1993-03-25 1994-09-29 Merck & Co., Inc. Inhibitor of vascular endothelial cell growth factor

Also Published As

Publication number Publication date
GB9410533D0 (en) 1994-07-13
WO1995032708A1 (en) 1995-12-07
CA2191070A1 (en) 1995-12-07
DE69527847T2 (de) 2003-04-30
ATE222488T1 (de) 2002-09-15
EP0771192A1 (en) 1997-05-07
AU692874B2 (en) 1998-06-18
DE69527847D1 (de) 2002-09-26
JPH10505321A (ja) 1998-05-26
US6121230A (en) 2000-09-19
EP0771192B1 (en) 2002-08-21
NZ285833A (en) 1999-09-29
AU2535395A (en) 1995-12-21

Similar Documents

Publication Publication Date Title
DE69527847D1 (de) Verwendung von anti-vegf-mitteln zur behandlung der endometriose
AU1565300A (en) Anti-germinating method for tubers and bulbs using eugenol and/or isoeugenol
UA56989C2 (uk) ФІЗІОЛОГІЧНО АКТИВНИЙ ПЕГ-КОН'ЮГАТ <font face="Symbol">a</font>-ІНТЕРФЕРОНУ, СПОСІБ ЙОГО ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ ТА СПОСІБ ЛІКУВАННЯ АБО ПРОФІЛАКТИКИ ІМУНОМОДУЛЯТОРНИХ ЗАХВОРЮВАНЬ
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
NO20075066L (no) Farmasoytisk sammensetning som inneholder isoflavoner
WO2002041837A3 (en) Treatment of mucositis
ES2167377T3 (es) Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos.
HU9503826D0 (en) Heterocycles useful as neurokinin antagonists
NO20054249L (no) Anvendelse av komposisjon for fremstilling av et farmasoytisk preparat for forhindring eller behandling av kloe hos en pasient
BR9913800A (pt) Método para tratar glaucoma, e, composição para tratar glaucoma
DE69627147D1 (de) Orale zubereitung enthaltend zonula occludens toxin und einen biologisch aktiven wirkstoff sowie deren verwendung
DE69932510D1 (de) Vaskularisierungsinhibitoren
DE60040753D1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
TR200200066T2 (tr) Migrenin tedavisi için seçici iGluR5 reseptör antagonistleri
FI972703A0 (fi) Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia
GR3019514T3 (en) Pharmaceutical preparation for the treatment of prolonged coagulation time
AR004089A1 (es) Utilizacion de un antagonista de substancia p en una composicion topica , como agente antitranspirante.
DE69805983D1 (de) Hustenhemmende, theobromine enthaltende zusammensetzungen
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
SE9802937D0 (sv) Novel compounds
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
PT684816E (pt) Composicoes antagonistas do receptor da 5-ht2 uteis no tratamento de doencas venosas
BR0105776A (pt) Tratamento de combinação para a depressão,a ansiedade e a psicose
TR200000291T2 (tr) Taşikinin reseptör antagonistleri olarak 2-asilaminopropanaminler.
DE69612056D1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel